19-10-2016 | Kidney cancer | News | Article
Cabozantinib ‘potential first-line option’ for advanced RCC
Cabozantinib significantly improves progression-free survival in newly diagnosed patients with intermediate- or poor-risk metastatic renal cell carcinoma, shows a head-to-head comparison with the standard of care sunitinib.
ESMO 2016; Copenhagen, Denmark
17-06-2016 | Kidney cancer | News | Article
News in brief
Cabozantinib extends advanced RCC overall survival
Patients with advanced or metastatic renal cell carcinoma derive a significant overall survival benefit from second-line treatment with the multi-tyrosine kinase inhibitor cabozantinib relative to everolimus.
15-01-2016 | Kidney cancer | News | Article
PD-L1 inhibition well-tolerated, active in metastatic RCC
The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.
J Clin Oncol 2016; Advance online publication
doctor_patient1, 3D breast cancer/© Sebastian Kaulitzki - Fotolia, Endoscope/© sudok1 / Fotolia, Male thyroid anatomy/© CLIPAREA.com / Fotolia, surgery11, Three way blank white sign/© MP - Fotolia, doctor_patient1